NASDAQ:MESO - Mesoblast Stock Price, Forecast & News

Mesoblast trades on the NASDAQ under the ticker symbol "MESO."

Mesoblast limited (NASDAQ:MESO) issued its quarterly earnings data on Monday, November, 25th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.09. The business had revenue of $17.05 million for the quarter, compared to analysts' expectations of $16.48 million. Mesoblast had a negative return on equity of 15.30% and a negative net margin of 342.39%. View Mesoblast's Earnings History.

Mesoblast is scheduled to release their next quarterly earnings announcement on Wednesday, February 19th 2020. View Earnings Estimates for Mesoblast.

6 brokerages have issued 1 year price objectives for Mesoblast's stock. Their forecasts range from $6.00 to $23.00. On average, they anticipate Mesoblast's stock price to reach $12.83 in the next year. This suggests a possible upside of 36.7% from the stock's current price. View Analyst Price Targets for Mesoblast.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mesoblast.

News stories about MESO stock have been trending somewhat positive on Monday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Mesoblast earned a news sentiment score of 1.7 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Mesoblast.

Some companies that are related to Mesoblast include Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Allogene Therapeutics (ALLO), Momenta Pharmaceuticals (MNTA), Iovance Biotherapeutics (IOVA), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Audentes Therapeutics (BOLD), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Regenxbio (RGNX), Cortexyme (CRTX), Editas Medicine (EDIT), SpringWorks Therapeutics (SWTX) and Alector (ALEC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Exelixis (EXEL), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Gilead Sciences (GILD), InterDigital Wireless (IDCC), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Crispr Therapeutics (CRSP), Progenics Pharmaceuticals (PGNX) and Portola Pharmaceuticals (PTLA).

(MESO) raised $69 million in an initial public offering on Friday, November 13th 2015. The company issued 5,700,000 shares at a price of $12.10 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

Mesoblast's stock is owned by a number of of institutional and retail investors. Top institutional investors include Penbrook Management LLC (0.23%).

MESO stock was bought by a variety of institutional investors in the last quarter, including Penbrook Management LLC.

Shares of MESO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MESO stock can currently be purchased for approximately $9.39.

Mesoblast has a market capitalization of $936.46 million and generates $16.72 million in revenue each year. The company earns $-89,800,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Mesoblast employs 81 workers across the globe.View Additional Information About Mesoblast.

The official website for Mesoblast is http://www.mesoblast.com/.

Mesoblast's mailing address is LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000. The company can be reached via phone at 61-3-9639-6036 or via email at [email protected]